Reducing anticholinergic burden in a frail elderly population: Translating the inappropriateness of anticholinergic drugs into patient-related outcomes
Metadata
Show metadataAppears in the following Collection
Abstract
List of papers. Papers I, III and IV are removed from the thesis due to publisher restrictions.Paper I: Stine Mjåvatn Jakobsen, Hege Kersten, Espen Molden. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. J Am Geriatr Soc. 2011. 59(3); 501–505. doi:10.1111/j.1532-5415.2010.03307.x
Paper II: Hege Kersten, Espen Molden, Tiril Willumsen, Knut Engedal, Torgeir Bruun Wyller. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Submitted version, published in: Br J Clin Pharmacol. 2012 68(3); 271-278. doi:10.1111/j.1365-2125.2012.04411.x
Paper III: Hege Kersten, Espen Molden, Inga Kristin Tolo, Eva Skovlund, Knut Engedal, Torgeir Bruun Wyller. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2012 Sep 14. doi:10.1093/gerona/gls176
Paper IV: Hege Kersten, Torgeir Bruun Wyller, Espen Molden, Poor-metabolizing phenotype of CYP2D6/2C19 is associated with elevated serum anticholinergic activity in elderly patients. Submitted version. Published as: Association Between Inherited CYP2D6/2C19 Phenotypes and Anticholinergic Measures in Elderly Patients Using Anticholinergic Drugs. Ther Drug Monit. 2013 Oct 1. [Epub ahead of print] doi:10.1097/FTD.0b013e31829da990